Our pipeline

Reverie’s differentiated pipeline is composed of wholly-owned drug candidates as well as candidates developed in collaboration with partner organizations, including Roche and Genentech. The assets in Reverie’s pipeline are designed to address critical limitations of current therapies, for example a lack of CNS-penetrance, or novel targets with the potential to address a serious unmet need. Reverie’s kinase-focused computational platform was critical to the discovery of every one of its drug candidates.

Candidate Name
Therapeutic Area
Early Discovery
Late Discovery
IND-Enabling
Clinical
RVL-101
CNS-penetrant CDK4/6 inhibitor
Cancer
RVL-102
Cancer
RVL-103
Cancer
Multiple Roche / GNE
Undisclosed
Undisclosed
Candidate
Name
Therapeutic
Area
Clinical
IND-
Enabling
Late
Discovery
Early
Discovery
RVL-101
CNS-penetrant CDK4/6 inhibitor
Cancer
RVL-102
Cancer
RVL-103
Cancer
Multiple
Roche / GNE
Undisclosed
Undisclosed
Send us a message, work with us, or say hello.
contact@reverielabs.com